Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis

The LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival. Suitable data sets were identified by a survey of published d...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of clinical oncology Ročník 31; číslo 18; s. 2303
Hlavní autoři: Collins, Marnie, Wilhelm, Miriam, Conyers, Rachel, Herschtal, Alan, Whelan, Jeremy, Bielack, Stefan, Kager, Leo, Kühne, Thomas, Sydes, Matthew, Gelderblom, Hans, Ferrari, Stefano, Picci, Piero, Smeland, Sigbjørn, Eriksson, Mikael, Petrilli, Antonio Sérgio, Bleyer, Archie, Thomas, David M
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 20.06.2013
Témata:
Adolescent
Adult
Age Factors
Bone Neoplasms - drug therapy
Bone Neoplasms - surgery
Chemotherapy, Adjuvant - adverse effects
Child
Combined Modality Therapy
Humans
Kaplan-Meier Estimate
Multivariate Analysis
Neoadjuvant Therapy - adverse effects
Neutropenia - chemically induced
Osteosarcoma - drug therapy
Osteosarcoma - surgery
Outcome Assessment, Health Care - statistics & numerical data
Prospective Studies
Regression Analysis
Sex Factors
Thrombocytopenia - chemically induced
Young Adult
ISSN:1527-7755, 1527-7755
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract The LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival. Suitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups. After accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated that a higher rate of chemotherapy-induced tumor necrosis was associated with longer survival (P < .001), as was female sex (P = .004) and the incidence of grade 3 or 4 mucositis (P = .03). Age group was not statistically significant in this landmark analysis (P = .12). Females reported higher rates of grade 3 or 4 thrombocytopenia relative to males (P < .001). Children reported the highest rates of grade 3 or 4 neutropenia (P < .001) and thrombocytopenia (P < .001). The achievement of good tumor necrosis was higher for females than for males (P = .002) and for children than for adults (P < .001). These results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes.
AbstractList The LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival.PURPOSEThe LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival.Suitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups.PATIENTS AND METHODSSuitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups.After accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated that a higher rate of chemotherapy-induced tumor necrosis was associated with longer survival (P < .001), as was female sex (P = .004) and the incidence of grade 3 or 4 mucositis (P = .03). Age group was not statistically significant in this landmark analysis (P = .12). Females reported higher rates of grade 3 or 4 thrombocytopenia relative to males (P < .001). Children reported the highest rates of grade 3 or 4 neutropenia (P < .001) and thrombocytopenia (P < .001). The achievement of good tumor necrosis was higher for females than for males (P = .002) and for children than for adults (P < .001).RESULTSAfter accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated that a higher rate of chemotherapy-induced tumor necrosis was associated with longer survival (P < .001), as was female sex (P = .004) and the incidence of grade 3 or 4 mucositis (P = .03). Age group was not statistically significant in this landmark analysis (P = .12). Females reported higher rates of grade 3 or 4 thrombocytopenia relative to males (P < .001). Children reported the highest rates of grade 3 or 4 neutropenia (P < .001) and thrombocytopenia (P < .001). The achievement of good tumor necrosis was higher for females than for males (P = .002) and for children than for adults (P < .001).These results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes.CONCLUSIONThese results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes.
The LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival. Suitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups. After accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated that a higher rate of chemotherapy-induced tumor necrosis was associated with longer survival (P < .001), as was female sex (P = .004) and the incidence of grade 3 or 4 mucositis (P = .03). Age group was not statistically significant in this landmark analysis (P = .12). Females reported higher rates of grade 3 or 4 thrombocytopenia relative to males (P < .001). Children reported the highest rates of grade 3 or 4 neutropenia (P < .001) and thrombocytopenia (P < .001). The achievement of good tumor necrosis was higher for females than for males (P = .002) and for children than for adults (P < .001). These results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes.
Author Kager, Leo
Bleyer, Archie
Ferrari, Stefano
Picci, Piero
Conyers, Rachel
Gelderblom, Hans
Thomas, David M
Collins, Marnie
Herschtal, Alan
Wilhelm, Miriam
Bielack, Stefan
Petrilli, Antonio Sérgio
Sydes, Matthew
Smeland, Sigbjørn
Whelan, Jeremy
Kühne, Thomas
Eriksson, Mikael
Author_xml – sequence: 1
  givenname: Marnie
  surname: Collins
  fullname: Collins, Marnie
  organization: Peter MacCallum Cancer Centre and Australasian Sarcoma Study Group, Melbourne, Australia
– sequence: 2
  givenname: Miriam
  surname: Wilhelm
  fullname: Wilhelm, Miriam
– sequence: 3
  givenname: Rachel
  surname: Conyers
  fullname: Conyers, Rachel
– sequence: 4
  givenname: Alan
  surname: Herschtal
  fullname: Herschtal, Alan
– sequence: 5
  givenname: Jeremy
  surname: Whelan
  fullname: Whelan, Jeremy
– sequence: 6
  givenname: Stefan
  surname: Bielack
  fullname: Bielack, Stefan
– sequence: 7
  givenname: Leo
  surname: Kager
  fullname: Kager, Leo
– sequence: 8
  givenname: Thomas
  surname: Kühne
  fullname: Kühne, Thomas
– sequence: 9
  givenname: Matthew
  surname: Sydes
  fullname: Sydes, Matthew
– sequence: 10
  givenname: Hans
  surname: Gelderblom
  fullname: Gelderblom, Hans
– sequence: 11
  givenname: Stefano
  surname: Ferrari
  fullname: Ferrari, Stefano
– sequence: 12
  givenname: Piero
  surname: Picci
  fullname: Picci, Piero
– sequence: 13
  givenname: Sigbjørn
  surname: Smeland
  fullname: Smeland, Sigbjørn
– sequence: 14
  givenname: Mikael
  surname: Eriksson
  fullname: Eriksson, Mikael
– sequence: 15
  givenname: Antonio Sérgio
  surname: Petrilli
  fullname: Petrilli, Antonio Sérgio
– sequence: 16
  givenname: Archie
  surname: Bleyer
  fullname: Bleyer, Archie
– sequence: 17
  givenname: David M
  surname: Thomas
  fullname: Thomas, David M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23669227$$D View this record in MEDLINE/PubMed
BookMark eNpNkDtPAzEQhC0URMKjp0IuaS7Y6_gedBDxVCQaqKONvQdGd3aw7yLlV_CXOSBIVLs7-maknUM28sETY6dSTCUIcfE4f5qCkDCdqWmpq3KPTaSGIisKrUf_9jE7TOldCDkrlT5gY1B5XgEUE_Z5TZ5q1yWO3nK0G4qJOG3ID5LzfBt6_0qRf-t94qGxw7HGzv0AkQy5jfOv3FNA-95v0HfcvFEbujeKuN7yOkQeUkchYTShxUteO28HS-J1DC1H3lKHGXpstsmlY7ZfY5PoZDeP2MvtzfP8Pls83T3MrxaZ0brqMirBWK3kCiqxArTGCqOMqvISVnktVA05KklFRYBGIpEdAC1FLrBWlZRwxM5_c9cxfPSUumXrkqGmweGTPi2lGgpSM5AwoGc7tF-1ZJfr6FqM2-VfifAFrpt53Q
CitedBy_id crossref_primary_10_1002_advs_202301806
crossref_primary_10_1007_s10616_025_00795_7
crossref_primary_10_1016_j_ejca_2018_11_027
crossref_primary_10_1186_s12935_020_01179_x
crossref_primary_10_1016_j_bbrc_2020_12_109
crossref_primary_10_3390_cancers15051520
crossref_primary_10_3390_ph15030362
crossref_primary_10_1002_cam4_5936
crossref_primary_10_3390_jcm9124070
crossref_primary_10_1158_1078_0432_CCR_18_4032
crossref_primary_10_1016_j_jbo_2020_100281
crossref_primary_10_1097_PAS_0000000000000995
crossref_primary_10_1097_MD_0000000000017381
crossref_primary_10_1002_jso_70087
crossref_primary_10_1007_s00330_015_3609_3
crossref_primary_10_1038_nrc3838
crossref_primary_10_12968_hmed_2024_0339
crossref_primary_10_14694_EdBook_AM_2014_34_259
crossref_primary_10_1097_MD_0000000000003420
crossref_primary_10_1002_ijc_32526
crossref_primary_10_1200_JCO_2017_75_1743
crossref_primary_10_1515_biol_2020_0086
crossref_primary_10_1517_17425255_2015_1038237
crossref_primary_10_1016_j_ejca_2022_06_008
crossref_primary_10_1080_15548627_2016_1239676
crossref_primary_10_1016_j_molstruc_2020_129773
crossref_primary_10_1016_j_ejca_2015_06_123
crossref_primary_10_1016_j_ocl_2015_06_011
crossref_primary_10_3389_fonc_2023_1220459
crossref_primary_10_1016_j_soc_2016_05_013
crossref_primary_10_1038_s41392_020_00414_1
crossref_primary_10_1002_cam4_1346
crossref_primary_10_1097_MPH_0000000000001332
crossref_primary_10_1177_107327481602300414
crossref_primary_10_1016_j_ejso_2020_03_218
crossref_primary_10_1002_jso_24074
crossref_primary_10_1097_PPO_0000000000000337
crossref_primary_10_1038_s41419_022_04744_6
crossref_primary_10_1089_jayao_2021_0180
crossref_primary_10_1007_s00262_025_04051_x
crossref_primary_10_1093_annonc_mdu153
crossref_primary_10_1038_srep12999
crossref_primary_10_1002_pbc_26457
crossref_primary_10_1111_ecc_12365
crossref_primary_10_1002_cam4_70206
crossref_primary_10_1016_j_ejso_2020_03_225
crossref_primary_10_1038_s41598_017_11208_x
crossref_primary_10_1016_j_mehy_2015_06_015
crossref_primary_10_1097_COC_0000000000000990
crossref_primary_10_3389_fonc_2022_1031787
crossref_primary_10_1186_1471_2407_14_744
crossref_primary_10_1097_MPH_0000000000001264
crossref_primary_10_1016_j_ejca_2017_09_036
crossref_primary_10_1016_j_ctrv_2018_05_001
crossref_primary_10_1002_pbc_25459
crossref_primary_10_1155_2014_402509
crossref_primary_10_1002_pbc_30649
crossref_primary_10_1007_s00280_018_3683_8
crossref_primary_10_4161_2162402X_2014_990800
crossref_primary_10_1038_s41416_024_02868_4
crossref_primary_10_1097_MPH_0000000000002003
crossref_primary_10_3389_fonc_2018_00133
crossref_primary_10_1002_cam4_6893
crossref_primary_10_4081_ejh_2023_3413
crossref_primary_10_1186_2045_3329_3_15
crossref_primary_10_1097_MPH_0000000000000192
crossref_primary_10_1186_s13018_023_03623_w
crossref_primary_10_1186_s12874_024_02416_x
crossref_primary_10_1186_s12885_025_13496_3
crossref_primary_10_1002_cncr_33273
crossref_primary_10_1007_s10147_019_01500_3
crossref_primary_10_1177_1176935117721691
crossref_primary_10_1097_MPH_0000000000000318
crossref_primary_10_3892_mmr_2017_8271
crossref_primary_10_1002_cjp2_29
crossref_primary_10_1089_jayao_2017_0007
crossref_primary_10_1002_advs_202205483
crossref_primary_10_3389_fimmu_2022_866892
crossref_primary_10_1590_1806_9282_61_06_497
crossref_primary_10_3390_cancers15071979
crossref_primary_10_3390_cancers15205044
crossref_primary_10_1134_S1607672921050197
crossref_primary_10_1016_j_canep_2024_102551
crossref_primary_10_1186_s12885_015_1894_5
crossref_primary_10_1038_s41419_019_1347_1
crossref_primary_10_1038_s41419_022_04980_w
crossref_primary_10_1136_bmjopen_2021_053083
crossref_primary_10_1016_j_omton_2024_200845
crossref_primary_10_1016_j_ejca_2024_115212
crossref_primary_10_1002_cjp2_219
crossref_primary_10_1186_s12967_019_2107_9
crossref_primary_10_1136_jitc_2020_000798
crossref_primary_10_1016_j_soncn_2015_05_003
crossref_primary_10_1111_cas_15521
crossref_primary_10_1016_j_heliyon_2024_e26681
crossref_primary_10_1186_s13046_019_1195_y
crossref_primary_10_1016_S1470_2045_14_71136_2
crossref_primary_10_1002_pbc_26533
crossref_primary_10_1159_000369975
crossref_primary_10_1007_s00280_019_03797_3
crossref_primary_10_3390_cells10112893
crossref_primary_10_1097_MPH_0000000000001506
crossref_primary_10_1089_jayao_2019_0085
crossref_primary_10_1016_j_ejcped_2023_100029
crossref_primary_10_1038_srep16991
crossref_primary_10_2147_CMAR_S358310
crossref_primary_10_1016_j_heliyon_2024_e27566
crossref_primary_10_1002_jso_25016
crossref_primary_10_1002_jso_25137
crossref_primary_10_1111_ecc_12291
crossref_primary_10_3389_fonc_2020_01198
crossref_primary_10_1016_j_canlet_2017_09_021
crossref_primary_10_1016_j_apsb_2021_08_015
crossref_primary_10_1158_1078_0432_CCR_15_1899
crossref_primary_10_1016_j_phymed_2023_154799
crossref_primary_10_1016_j_ejca_2025_115535
crossref_primary_10_1016_j_clinthera_2014_02_018
crossref_primary_10_1016_j_jos_2017_03_008
crossref_primary_10_1016_j_ocl_2015_08_022
crossref_primary_10_1007_s13193_024_02087_6
crossref_primary_10_3390_cancers16132351
crossref_primary_10_1136_bmjopen_2021_053456
crossref_primary_10_1007_s10260_022_00647_0
crossref_primary_10_1016_j_jelechem_2018_07_034
crossref_primary_10_3389_fgene_2022_1081478
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1200/JCO.2012.43.8598
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1527-7755
ExternalDocumentID 23669227
Genre Research Support, Non-U.S. Gov't
Meta-Analysis
Journal Article
GrantInformation_xml – fundername: Medical Research Council
  grantid: MC_U122861384
– fundername: Department of Health
GroupedDBID ---
.55
0R~
18M
2WC
34G
39C
4.4
53G
5GY
5RE
8F7
AARDX
AAWTL
AAYEP
ABBLC
ABJNI
ABOCM
ACGFO
ACGFS
ACGUR
ADBBV
AEGXH
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C45
CGR
CS3
CUY
CVF
DIK
EBS
ECM
EIF
EJD
F5P
F9R
FBNNL
FD8
GX1
H13
HZ~
IH2
KQ8
L7B
LSO
MJL
N9A
NPM
O9-
OK1
OVD
OWW
P2P
QTD
R1G
RHI
RLZ
RUC
SJN
TEORI
TR2
TWZ
UDS
VVN
WH7
X7M
YFH
YQY
7X8
ID FETCH-LOGICAL-c559t-e82cd531b290b2adcd0c3c39682b6f03f26a31e79e2ac1aeedd0c51060af39112
IEDL.DBID 7X8
ISICitedReferencesCount 162
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000320446700016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1527-7755
IngestDate Fri Sep 05 07:56:00 EDT 2025
Mon Jul 21 06:05:04 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 18
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c559t-e82cd531b290b2adcd0c3c39682b6f03f26a31e79e2ac1aeedd0c51060af39112
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2012.43.8598
PMID 23669227
PQID 1369234212
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1369234212
pubmed_primary_23669227
PublicationCentury 2000
PublicationDate 2013-06-20
PublicationDateYYYYMMDD 2013-06-20
PublicationDate_xml – month: 06
  year: 2013
  text: 2013-06-20
  day: 20
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of clinical oncology
PublicationTitleAlternate J Clin Oncol
PublicationYear 2013
SSID ssj0014835
Score 2.5005698
SecondaryResourceType review_article
Snippet The LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 2303
SubjectTerms Adolescent
Adult
Age Factors
Bone Neoplasms - drug therapy
Bone Neoplasms - surgery
Chemotherapy, Adjuvant - adverse effects
Child
Combined Modality Therapy
Humans
Kaplan-Meier Estimate
Multivariate Analysis
Neoadjuvant Therapy - adverse effects
Neutropenia - chemically induced
Osteosarcoma - drug therapy
Osteosarcoma - surgery
Outcome Assessment, Health Care - statistics & numerical data
Prospective Studies
Regression Analysis
Sex Factors
Thrombocytopenia - chemically induced
Young Adult
Title Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/23669227
https://www.proquest.com/docview/1369234212
Volume 31
WOSCitedRecordID wos000320446700016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwELVoQYhLy1cLpaCphDhh2NiJE3OpKAIhJLZ7AGlvq1nbqbbSJoCzSPsr-MsdJ0Z7QkLqJYd8SIlm_Pzi8bzH2KEulc5s4rjDNOepVYoTb054TmzYImEmis5sIu_3i-FQD-KCm4_bKl8xsQVqW5uwRn6aSEVcJNQvfz488uAaFaqr0ULjA1uWRGXClq58uKgipEVrsBmcW4lFZlksU1JinN5c_A77usRJKk-KTBdvE8x2orn6_L-vuM4-RYoJ511ObLAlV22y1dtYRN9kR4NOrnp-DHeL7it_DEcwWAhZz7fYyy8CwnLSeMDKAgbrZu-glXzyMKlgHpDCPUE4P_NQB8NviEKtHghK3SQsV0DlarR_Z8TZG6AcmcamrzkQYYbQZFJ7Gm71FM-gLaFXfzyEthdAmLoGOUbhlG12f3V5d3HNo4EDN_Sj0nBXCGNpkI-F7o0FWmN7RhqpVSHGquzJUiiUicu1E2gSpOmabiCQUD0sJaGw-MI-VnXldhiMtRZBSFtLk6WYCZ0mCUGzIjhJlDbFLvvxGpMRDZBQ9UD6upkfLaKyy752gR09dEoeIyEVXRT5t3c8vcfWRGeFQcjynS2XBA9un62Y52binw7azKNjf3D7D70t5Yg
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Benefits+and+adverse+events+in+younger+versus+older+patients+receiving+neoadjuvant+chemotherapy+for+osteosarcoma%3A+findings+from+a+meta-analysis&rft.jtitle=Journal+of+clinical+oncology&rft.au=Collins%2C+Marnie&rft.au=Wilhelm%2C+Miriam&rft.au=Conyers%2C+Rachel&rft.au=Herschtal%2C+Alan&rft.date=2013-06-20&rft.issn=1527-7755&rft.eissn=1527-7755&rft.volume=31&rft.issue=18&rft.spage=2303&rft_id=info:doi/10.1200%2FJCO.2012.43.8598&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon